The overall Otsuka group is globally engaged in a number of businesses including pharmaceutical, nutraceutical, consumer products, medical devices and other products. Otsuka’s mission is to create new products for better health worldwide.
Veryan is engaged in commercial operations selling its products in the UK and other European countries. Veryan is also engaged in research and development in the vascular device field, with activities ranging from early stage development, through to clinical trials and regulatory approval.
This strategy applies to Veryan Medical Limited, Veryan Holdings Limited, and Otsuka Medical Devices UK Limited, and it is regarded that this publication complies with the duty under paragraphs 16 and 19 of Schedule 19 to the Finance Act 2016. In this report, references to “Veryan” or “the Company” are references to Veryan Medical Limited, Veryan Holdings Limited, and Otsuka Medical Devices UK Limited.
Veryan’s tax strategy and policy comprises four key components: